Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Type I diabetes-associated tolerogenic properties of interleukin-2.

Chentoufi AA, Gaudreau S, Nguyen A, Sabha M, Amrani A, Elghazali G.

Clin Dev Immunol. 2011;2011:289343. doi: 10.1155/2011/289343. Epub 2011 May 10.

2.

Control of type 1 autoimmune diabetes by naturally occurring CD4+CD25+ regulatory T lymphocytes in neonatal NOD mice.

Piccirillo CA, Tritt M, Sgouroudis E, Albanese A, Pyzik M, Hay V.

Ann N Y Acad Sci. 2005 Jun;1051:72-87. Review.

PMID:
16126946
3.

The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies.

Chistiakov DA, Voronova NV, Chistiakov PA.

Immunol Lett. 2008 Jun 15;118(1):1-5. doi: 10.1016/j.imlet.2008.03.002. Epub 2008 Apr 1. Review.

PMID:
18417224
4.

Advances in type I diabetes associated tolerance mechanisms.

Chentoufi AA, Binder NR, Berka N, Abunadi T, Polychronakos C.

Scand J Immunol. 2008 Jul;68(1):1-11. doi: 10.1111/j.1365-3083.2008.02120.x. Epub 2008 May 9. Review.

5.

Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease.

Sgouroudis E, Piccirillo CA.

Diabetes Metab Res Rev. 2009 Mar;25(3):208-18. doi: 10.1002/dmrr.945. Review.

PMID:
19214972
6.

Dysrulation of T cell peripheral tolerance in type 1 diabetes.

Tisch R, Wang B.

Adv Immunol. 2008;100:125-49. doi: 10.1016/S0065-2776(08)00805-5. Review.

PMID:
19111165
7.

CD3 antibody treatment stimulates the functional capability of regulatory T cells.

Chatenoud L.

Novartis Found Symp. 2003;252:279-86; discussion 286-90. Review.

PMID:
14609225
8.

Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes.

Li CR, Baaten BJ, Bradley LM.

J Mol Cell Biol. 2012 Feb;4(1):38-47. doi: 10.1093/jmcb/mjr040. Epub 2011 Nov 24. Review.

9.

CD8+ T cells in type 1 diabetes.

Tsai S, Shameli A, Santamaria P.

Adv Immunol. 2008;100:79-124. doi: 10.1016/S0065-2776(08)00804-3. Review.

PMID:
19111164
10.

Role of regulatory T cells for the treatment of type 1 diabetes mellitus.

Jaeckel E, Mpofu N, Saal N, Manns MP.

Horm Metab Res. 2008 Feb;40(2):126-36. doi: 10.1055/s-2008-1042427. Review.

PMID:
18283631
11.

Plasmacytoid dendritic cells in autoimmune diabetes - potential tools for immunotherapy.

Nikolic T, Welzen-Coppens JM, Leenen PJ, Drexhage HA, Versnel MA.

Immunobiology. 2009;214(9-10):791-9. doi: 10.1016/j.imbio.2009.06.002. Epub 2009 Jul 22. Review.

PMID:
19628297
12.

Breakdown in peripheral tolerance in type 1 diabetes in mice and humans.

Jeker LT, Bour-Jordan H, Bluestone JA.

Cold Spring Harb Perspect Med. 2012 Mar;2(3):a007807. doi: 10.1101/cshperspect.a007807. Review.

13.

Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2.

Dwyer CJ, Ward NC, Pugliese A, Malek TR.

Curr Diab Rep. 2016 Jun;16(6):46. doi: 10.1007/s11892-016-0739-1. Review.

PMID:
27076179
14.

Autologous regulatory T cells for the treatment of type 1 diabetes.

Thompson JA, Perry D, Brusko TM.

Curr Diab Rep. 2012 Oct;12(5):623-32. doi: 10.1007/s11892-012-0304-5. Review.

PMID:
22843491
15.

New Molecular and Cellular Mechanisms of Tolerance: Tolerogenic Actions of IL-2.

PĂ©rol L, Piaggio E.

Methods Mol Biol. 2016;1371:11-28. doi: 10.1007/978-1-4939-3139-2_2. Review.

PMID:
26530792
16.

IL-2 therapy in type 1 diabetes: "Trials" and tribulations.

Long SA, Buckner JH, Greenbaum CJ.

Clin Immunol. 2013 Dec;149(3):324-31. doi: 10.1016/j.clim.2013.02.005. Epub 2013 Feb 22. Review.

PMID:
23499139
17.

Tolerogenic Nanoparticles to Treat Islet Autoimmunity.

Neef T, Miller SD.

Curr Diab Rep. 2017 Aug 8;17(10):84. doi: 10.1007/s11892-017-0914-z. Review.

PMID:
28791576
18.

Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment.

Hotta-Iwamura C, Tarbell KV.

J Leukoc Biol. 2016 Jul;100(1):65-80. doi: 10.1189/jlb.3MR1115-500R. Epub 2016 Jan 20. Review.

19.

Immunotherapy of type 1 diabetes: where are we and where should we be going?

Luo X, Herold KC, Miller SD.

Immunity. 2010 Apr 23;32(4):488-99. doi: 10.1016/j.immuni.2010.04.002. Review.

20.

Insights into type 1 diabetes from the autoimmune polyendocrine syndromes.

Cheng MH, Anderson MS.

Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):271-8. doi: 10.1097/MED.0b013e32836313eb. Review.

Supplemental Content

Support Center